COVID-19

Novavax, the biotechnology company developing next-generation vaccines for serious infectious diseases, has announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase III clinical trial conducted in the UK. The study assessed efficacy during a period with high transmission and with a new UK […]

Mammoth Biosciences has announced an agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent’s Bravo automation workstation and Mammoth Biosciences’ DETECTR BOOSTTM assay. Together, the DETECTR BOOSTTM SARS-CoV-2 kit and Agilent automated liquid handling system would provide a complete workflow for high-throughput COVID-19 testing – a […]

A UK biotech company developing a novel treatment for Covid-19 has welcomed NHS plans to make Covid-19 treatments available to patients as soon as possible. The CEO of NHS England, Sir Simon Stevens, recently highlighted the importance of therapeutic treatments to help the UK return to a more normal way of life, predicting that many […]

By David Berd, Chief Medical Officer, BioVaxys. It has been a little more than a year since COVID-19 was released on the world causing widespread respiratory illness, death and major disruptions in the world’s economies and in people’s daily lives.  From the beginning of the pandemic, it was recognised that a vaccine that prevented the acquisition […]

The rapid spread of the newly emerging SARS-CoV-2 virus variant B.1.1.7 in Great Britain and other countries shows changes in the genome of the SARS-CoV-2 virus can lead to new biological properties. Most of the approximately 12,000 mutations in the genome of the SARS-CoV-2 virus that have been identified since February 2020 so far did […]

Against the backdrop of COVID-19 disruption, there has been good progress made with European IDMP data standards. Remco Munnik of Iperion Life Sciences Consultancy looks back at the main IDMP developments in 2020 – and looks ahead to a future better supported by data standardisation. The COVID-19 pandemic has highlighted the potential for global data […]

As mRNA has gone from the unknown to arguably one of the most discussed areas of science in our lifetimes, Lu Rahman looks at the story behind its role in the fight against COVID-19 and why we should thank those working to create vaccines. In less than the spaceof a year, vaccines have become the […]

Novavax, the late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has finalised an agreement with the government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional […]

Last spring, as healthcare providers and scientists around the world scrambled to treat a surge of patients infected with a virus that experts knew little about, one thing quickly became clear: SARS-CoV-2 strikes people differently. Faced with solving a mega-puzzle on a timer when minutes cost lives, clinical practice early in the pandemic became a […]

Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Fluidic Analytics’ application note explains why current technologies provide only an incomplete understanding of the immune response against SARS-CoV-2. It demonstrates […]